Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionXponance, Inc.
Latest Disclosed Ownership29,871 shares
Latest Disclosed Value $ 9,883,418
Xponance, Inc. reports 9.31% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 13, 2026 - Xponance, Inc. filed a 13F-HR form disclosing ownership of 29,871 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $8,534,145 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 27,328 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 9.31% during the quarter. The current value of the position is $7,521,518 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 29,871 2,543 9.31 9,883 -9.05 0.0702
2026-02-12 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,328 1,176 4.50 10,867 -8.88 0.0815
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,152 1,135 4.54 11,925 46.19 0.0944
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,017 1,860 8.03 8,158 30.47 0.0682
2025-05-01 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 23,157 701 3.12 6,253 18.32 0.0605
2025-02-11 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,456 1,806 8.75 5,284 -6.96 0.0482
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,650 -426 -2.02 5,679 10.90 0.0548
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,076 1,378 7.00 5,121 74.01 0.0524
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,698 5,609 39.81 2,944 9.16 0.0308
2024-01-31 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,089 -895 -5.97 2,697 1.62 0.0323
2023-10-24 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,984 109 0.73 2,654 -6.09 0.0361
2023-07-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,875 -1,963 -11.66 2,825 -16.22 0.0376
2023-04-18 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,838 161 0.97 3,373 -14.91 0.0493
2023-01-24 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,677 2,352 16.42 3,963 38.23 0.0642
2022-10-24 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,325 22 0.15 2,867 37.44 0.0551
2022-08-02 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,303 520 3.77 2,086 -7.33 0.0419
2022-04-20 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,783 387 2.89 2,251 -0.92 0.0374
2022-01-31 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,396 9 0.07 2,272 -10.13 0.0356
2021-11-05 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,387 -326 -2.38 2,528 8.73 0.0480
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 13,713 1,658 13.75 2,325 36.60 0.0427
2021-05-10 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,055 -24 -0.20 1,702 8.41 0.0361
2021-02-11 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,079 114 0.95 1,570 -9.87 0.0342
2020-10-26 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,965 137 1.16 1,742 -0.57 0.0428
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,828 11,828 1,752 0.0452
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.